m-EASIX (better than EASIX) predicts severe CAR T-cell toxicities, worse overall survival, and discriminates cytokine release syndrome from sepsis Front Immunol
European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple Myeloma CL LYMPH MYELOM LEUK
In Vitro Evidence of Therapy-Induced Suppression of Prothrombotic and Proinflammatory Phenotypes in Severe COVID-19 THROMB HAEMOSTASIS
Allo-HCT with post-transplant cyclophosphamide in older adults: similar safety and a viable option compared to younger adults Front Immunol
One-year consolidation with Ponatinib 15 mg in chronic myeloid leukaemia on deep molecular response with Imatinib Ann Hematol
Prostate Cancer Incidence by Age and Clinicopathological Characteristics: A Population-Based Study in Girona, Spain, 2010 to 2021 CLIN GENITOURIN CANC
Breast cancer incidence, by stage at diagnosis, and mortality in 21 European countries in the era of mammography screening: an international population-based study LANCET REG HEALTH-EU
Red blood cell immunization as an independent predictor of survival in the myelodysplastic syndromes BRIT J HAEMATOL
EASIX, a new tool to predict response and refractoriness in immune-mediated thrombotic thrombocytopenic purpura Front Immunol
Conjugation strategy shapes antitumor efficacy and enables dose-sparing in non-antibody protein nanoconjugates Mater Today Bio